Sunder Biomedical Tech. Co., Ltd. (4115) Fair Value & Analysis
Healthcare · TW · Market cap 475M TWD
Strengths
Risks
Fair value as of: Aug 20, 2026
From 4 valuation models · updated 3 days ago
Share price −4.7% over the past month.
Below-average quality, screening 48% undervalued on our models.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
What matters now
- The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
- Solid quality (46/100) at a price below fair value, the discount is the argument here, not the business quality.
- A fairly wide model range (7.41 TWD to 15.51 TWD) leaves room in how you read the outcome.
Price vs Fair Value (9 months)
White line = price, green steps = our fair value per fiscal year. As of Aug 20, 2026.
How to read this chart
9‑month range 6.75 TWD – 11.15 TWD · fair‑value band 7.41 TWD – 15.51 TWD · the 7.76 TWD price screens below the 11.46 TWD fair value. As of Aug 20, 2026.
Analysis
Sunder Biomedical Tech. Co., Ltd. (4115) currently trades at 7.76 TWD, while our model-based Fair Value estimate is 11.46 TWD, implying the stock looks roughly 47.7% undervalued today. The Quality Score stands at 46/100 (below-average quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low), always confirm before acting.
Net debt stands at 284M TWD. Fundamentals as of Aug 20, 2026
Our scenario range runs from 7.41 TWD (bear case) to 15.51 TWD (bull case); at 7.76 TWD, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 36% below its 52-week high and 19% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -46% fair-value upside, at 48%, 4115 screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 4 models by family
Widest divergence: Multiples (15.64 TWD) versus Dividend Discount (3.21 TWD). Highest evidence: Gordon GGM (70).
Notify me when 4115 reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
Figures from reported company fundamentals · as of Aug 20, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 43 · Market factors (momentum, volatility) 22
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Sunder Biomedical Tech. Co., Ltd. engages in the manufacture and sale of medical devices. It offers endoscopy vision set, suction irrigation set, smoke filter, endo bag, blood line set for hemodialysis, A.V. fistula needle, I.V. administration, volume control I.V. administration, extension tube.
Full company description
Sunder Biomedical Tech. Co., Ltd. engages in the manufacture and sale of medical devices. It offers endoscopy vision set, suction irrigation set, smoke filter, endo bag, blood line set for hemodialysis, A.V. fistula needle, I.V. administration, volume control I.V. administration, extension tube. surgical tubing set, PVC compounds for medical application, transducer protector, melt blown nonwoven fabric and mask, and protective goggles, as well as components comprising caps for dialyzer adaptor and for female luer lock. The company was founded in 1998 and is headquartered in Yúnlín, Taiwan.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Sunder Biomedical Tech. Co., Ltd. reported revenue of 753M TWD in FY2025 versus 1.1B TWD in FY2021, a compound −9.8%/yr. Reported net income was −16.3M TWD in FY2025.
Watch 4115: get an alert when its fair value changes →
Peer Group
Medical Instruments & Supplies · 205 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Medical Instruments & Supplies stocks, each showing price versus our Fair Value estimate (as of Aug 20, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Intuitive Surgical, Inc ISRG | $378.81 | $150.04 | -60% |
| EssilorLuxottica Société anonyme 1EL | €164.40 | €68.55 | -58% |
| Medline Inc MDLN | $35.50 | $30.15 | -15% |
| Becton, Dickinson and Company BDX | $182.09 | $100.46 | -45% |
| Alcon Inc ALC | $73.58 | $39.78 | -46% |
| ResMed Inc RMD | $231.52 | $187.89 | -19% |
| West Pharmaceutical Services, Inc WST | $352.29 | $141.58 | -60% |
| Sartorius Stedim Biotech S.A DIM | €180.30 | €48.88 | -73% |
| Coloplast A/S COLOB | kr 435.80 | kr 382.22 | -12% |
| Gan & Lee Pharmaceuticals., a biopharmaceutical company, 603087 | ¥77.48 | ¥27.22 | -65% |
Compare Sunder Biomedical Tech. Co., Ltd. with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Discover undervalued stocks
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is Sunder Biomedical Tech. Co., Ltd. (4115) overvalued or undervalued?
What is the fair value of 4115?
What is the quality score of 4115?
What is the net profit margin of 4115?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Sunder Biomedical Tech. Co., Ltd. and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.